Last reviewed · How we verify
NCT03068572
Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD
trial in Gastroesophageal Reflux Disease in 90 participants. Status unknown.
30 October 2017
Quick facts
| Lead sponsor | Affiliated Hospital to Academy of Military Medical Sciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 15 January 2017 |
| Primary completion | 30 October 2017 |
| Estimated completion | 30 December 2017 |
| Sites | 1 location across China |
Conditions studied
- Gastroesophageal Reflux Disease — all drugs for Gastroesophageal Reflux Disease →
- Minimal Change Disease — all drugs for Minimal Change Disease →
- Non-Reflux Esophagitis — all drugs for Non-Reflux Esophagitis →
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Who can join
Adults 18 to 80, any sex, with Gastroesophageal Reflux Disease or Minimal Change Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Linked color imaging(LCI),a new system for endoscopy modality,creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of magnifying blue laser imaging(BLI) technology.LCI makes red areas appear redder and white areas appear whiter.Thus,it is easier to recognize a slight difference in color of the mucosa.This is a study to assess the effectiveness of LCI for diagnosing esophageal minimal endoscopic lesions and Los Angeles classification system when compared to conventional white-light endoscopy (WLI).Gastroesophageal reflux disease(GERD) is a common disease that be defined as a condition which develops when the reflux of stomach contents cause troublesome symptoms and/or complications.Esophageal injury was classified according to the Los Angeles classification system,Non-erosive reflux disease(NERD) is defined by the presence of troublesome reflux-associated symptoms and the absence of mucosal breaks at endoscopy,which includes minimal change oesophagitis and no endoscopic abnormalities.LCI improved the visualization of the squamocolumnar junction (SCJ) by enhancing the contrast,mucosa minimal changes could be seen more easily and clearly with LCI than with standard white-light endoscopy.By comparing White-light endoscopy and LCI,it will show if there is any comparable advantage to using one or the other for lesion detection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Linked color imaging improves detection of minimal change esophagitis in non-erosive reflux esophagitis patients.
Deng P, Min M, Dong T, Bi Y, et al · · 2018 · cited 12× · PMID 30302374 · DOI 10.1055/a-0602-3997
Verify or expand the search:
- PubMed search for NCT03068572
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastroesophageal Reflux Disease
Currently open trials in the same condition.
- NCT06783751 — Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG) · NA · recruiting
- NCT06348420 — Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment · NA · recruiting
- NCT06991348 — Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Dise · Phase 4 · recruiting
- NCT06732661 — Preserving the Pre-cardial Fat Pad During Sleeve Gastrectomy on Postoperative Gastroesophageal Reflux · NA · active not recruiting
- NCT05514769 — Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer · NA · recruiting
Other Affiliated Hospital to Academy of Military Medical Sciences trials
Trials by the same sponsor.
- NCT06986434 — CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differenti · EARLY_PHASE1 · not yet recruiting
- NCT07416682 — CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms · EARLY_PHASE1 · not yet recruiting
- NCT06834529 — CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma · Phase 1, PHASE2 · recruiting
- NCT06152263 — LCI in Chronic Atrophic Gastritis and Early Gastric Cancer · unknown
- NCT05645601 — CAR-NK Targeted CD19 for r/r B-cell Malignancies · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03068572 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital to Academy of Military Medical Sciences
- Last refreshed: 19 September 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03068572.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing